SLC5A2 and heart failure: The EMPA-REG OUTCOME trial, a cardiovascular outcome trial (CVOT) of the SGLT2 inhibitor empagliflozin, demonstrated that empagliflozin was superior to a matching placebo in reducing cardiovascular events, including mortality and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular diseases (7, 8) (Table 1).